Edition:
United States

Agios Pharmaceuticals Inc (AGIO.O)

AGIO.O on Nasdaq

41.55USD
13 Jan 2017
Change (% chg)

$-0.06 (-0.14%)
Prev Close
$41.61
Open
$41.61
Day's High
$42.45
Day's Low
$41.31
Volume
380,451
Avg. Vol
868,435
52-wk High
$67.74
52-wk Low
$33.50

Latest Key Developments (Source: Significant Developments)

Agios announces new clinical data from dose-escalation portion of Phase 1 trial of single agent AG-120 showing durable molecular responses in patients with advanced Hematologic Malignancies
Monday, 5 Dec 2016 07:30pm EST 

Agios Pharmaceuticals Inc : For relapsed/refractory acute myeloid leukemia patients, overall response rate of 33% ,complete remission rate of 16% .Agios announces new clinical data from dose-escalation portion of phase 1 trial of single agent AG-120 showing durable molecular responses in patients with advanced Hematologic Malignancies.  Full Article

Agios Pharmaceuticals appoints Andrew Hirsch as chief financial officer
Tuesday, 16 Aug 2016 07:30am EDT 

Agios Pharmaceuticals Inc : Appoints Andrew Hirsch as chief financial officer . Glenn Goddard, senior vice president of finance, will be leaving company at end of September to pursue other opportunities .Andrew Hirsch most recently served as president and chief executive officer of Bind Therapeutics.  Full Article

Agios Pharmaceuticals reports qtrly loss per share $1.47
Thursday, 4 Aug 2016 07:01am EDT 

Agios Pharmaceuticals Inc : Agios reports second quarter 2016 financial results . Collaboration revenue was $7.0 million for quarter ended June 30, 2016, compared to $13.2 million for comparable period in 2015 .Qtrly loss per share $1.47.  Full Article

Agios sees 2016 ending cash position of more than $390 mln
Tuesday, 17 May 2016 04:02pm EDT 

Agios Pharmaceuticals Inc : Agios updates 2016 financial guidance . Expects 2016 ending cash position of more than $390 million .Expects that its cash would be sufficient to fund its operating expenses and capital expenditure requirements through mid-2018.  Full Article

Agios Pharmaceuticals, Celgene establish new collaboration in metabolic immuno-oncology
Tuesday, 17 May 2016 04:01pm EDT 

Agios Pharmaceuticals Inc : Agios and Celgene establish new collaboration in metabolic immuno-oncology and amend certain rights from 2010 agreement . Agios to receive $200 million upfront payment . Ag-120 rights outside United States transferred to Agios . Companies modified certain rights from their 2010 collaboration . As of August 15, 2016, neither party will have financial or other obligations to each other related to AG-120 . After expiration of discovery phase of 2010 agreement, other cancer metabolism programs discovered at co will remain owned by co .Exploratory research, drug discovery and early development will be led by Agios.  Full Article

Agios Pharmaceuticals announces data from ongoing phase 1 Trial of AG-120
Saturday, 5 Dec 2015 09:01am EST 

Agios Pharmaceuticals:Says new data from the ongoing Phase 1 study evaluating single agent AG-120, a first-in-class, oral, selective, potent inhibitor of mutant isocitrate dehydrogenase-1 (IDH1), in advanced hematologic malignancies.The data are being presented at the 2015 American Society of Hematology Annual Meeting and Exposition (ASH) taking place December 5-8, 2015 in Orlando.AG-120 is being developed in collaboration with Celgene.  Full Article

Agios Pharmaceuticals announces new data from ongoing phase 1 dose escalation and expansion trial of AG-221
Friday, 12 Jun 2015 06:00am EDT 

Agios Pharmaceuticals Inc:Announces new data from ongoing phase 1 dose escalation and expansion trial of ag-221 showing durable clinical activity in patients with advanced hematologic malignancies.Says 125-patient expansion cohort and global registration-enabling program remain on track.The study had an overall response rate of 40 percent and a complete remission rate of 16 percent.Idh2-mutant inhibitor shows durable responses of more than 15 months in patients with advanced acute myeloid leukemia.The overall safety profile observed was consistent with previously reported data.Says a maximum tolerated dose has not been reached.New data from the ongoing phase 1 study of AG-221 to be presented at 20(th)congress of European hematology association (EHA).  Full Article

Agios Pharmaceuticals says new data from ongoing phase 1 trial of AG-120
Friday, 12 Jun 2015 05:55am EDT 

Agios Pharmaceuticals:Announces new data from ongoing phase 1 trial of ag-120 showing durable clinical activity in patients with advanced hematologic malignancies.Says three expansion cohorts and global registration-enabling program remain on track.Idh1- mutant inhibitor shows durable responses of up to 11 months in patients.Says maximum tolerated dose (mtd) has not been reached.Says overall safety profile remains consistent with 40 additional patients treated as of the last analysis.Data as of may 1, from 57 patients with advanced hematologic malignancies showed a favorable safety profile.To present first data from the phase 1 trial in advanced solid tumors at a medical conference in the second half of 2015.  Full Article

Agios Pharmaceuticals reports new final data from phase 1 MAD study for pyruvate kinase deficiency
Friday, 12 Jun 2015 01:00am EDT 

Agios reports new, final data from phase 1 multiple ascending dose (mad) study in healthy volunteers for ag-348, an investigational medicine for pyruvate kinase (pk) deficiency:Says the study showed that ag-348 was well tolerated in phase 1 mad trial.Says thirty-two of 36 healthy volunteers receiving ag-348 completed the study.Says two volunteers receiving ag-348 withdrew due to adverse events.  Full Article

Agios Pharmaceuticals announces FDA Orphan Drug Designation Granted to AG-120 for treatment of IDH1-Mutant Positive Acute Myelogenous Leukemia
Wednesday, 10 Jun 2015 04:39pm EDT 

Agios Pharmaceuticals, Inc:Says U.S. Food and Drug Administration (FDA) has granted the company orphan drug designation for AG-120 for treatment of patients with acute myelogenous leukemia (AML).Says AG-120 is an oral, first-in-class IDH1 mutant inhibitor being evaluated in a Phase 1 clinical trial in patients with advanced hematologic malignancies that carry an IDH1 mutation.  Full Article